Sign in →

Test Code LAB3589 Zonisamide, Serum

Additional Codes

 

Test Name in EPIC EPIC Test Code Mnemonic Mayo Test ID
ZONISAMIDE, S LAB3589 ZONIS ZONI

 

Reporting Name

Zonisamide, S

Useful For

Monitoring zonisamide therapy; recommended for all patients to ensure appropriate dosing

 

Assessing medication compliance

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Container/Tube: Red top

Specimen Volume: 1 mL

Collection Instructions: Sample must be centrifuged and serum aliquoted off within 2 hours of draw.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reject Due To

Hemolysis

Mild OK; Gross OK

Lipemia

Mild OK; Gross OK

Icterus

Mild OK; Gross OK

Other

Serum Gel, SST

 

Reference Values

10-40 mcg/mL

Day(s) and Time(s) Performed

Monday through Saturday

CPT Code Information

80203

LOINC Code Information

Test ID Test Order Name Order LOINC Value
ZONI Zonisamide, S In Process

 

Result ID Test Result Name Result LOINC Value
83685 Zonisamide, S 29620-2

Analytic Time

Same day/1 day

Cautions

Rufinamide is a known interference of this assay. Patients who are coadministered zonisamide and rufinamide may have falsely elevated and uninterpretable zonisamide concentrations reported by this assay.

 

Serum zonisamide will be increased with hemolysis.

Method Description

Samples are extracted with analyte detection by mass spectrometry.(Unpublished Mayo method)

Interpretation

Steady-state zonisamide concentration in a trough specimen drawn just before next dose correlates with patient response, but not with dose. Optimal response to zonisamide occurs when trough zonisamide concentration is in the range of 10 to 40 mcg/mL. Peak serum concentration for zonisamide occurs 2 to 6 hours after dose, and time to peak is affected by food intake.

 

Because carbamazepine activates glucuronidation, patients taking carbamazepine concomitantly with zonisamide have significantly lower zonisamide concentrations compared to patients on the same dose not receiving carbamazepine.

Specimen Retention Time

14 days

Clinical Information

Zonisamide (Zonegran) is approved as adjunctive therapy for partial seizures refractory to therapy with traditional anticonvulsants. Zonisamide is the pharmacologically active agent; metabolites are not active. Essentially 100% of the zonisamide dose is absorbed. Zonisamide binds to erythrocytes; approximately 88% of circulating zonisamide is bound in erythrocytes. Because the erythrocyte-bound zonisamide is inactive, and binding varies with blood concentration, the relationship between serum level and dose is not linear. Time to peak zonisamide concentration is 2 to 4 hours; time to peak is delayed by co-administration with food to 4 to 6 hours. Zonisamide is metabolized by N-acetyl transferase (NAT1), cytochrome P4503A4 (CyP3A4), and uridine diphosphate glucuronidation (UDPG). Zonisamide is eliminated in the urine predominantly as the parent drug (35%), N-acetyl zonisamide (15%), and as the glucuronide ester of reduced zonisamide (50%). Co-administration of drugs that affect NAT1, CyP3A4, and UDPG activity, such as phenytoin and carbamazepine, will decrease zonisamide concentration.

 

A typical zonisamide dose administered to an adult is 400 to 600 mg/day, administered in 2 divided doses. The apparent volume of distribution of zonisamide is 1.5 L/kg. Approximately 40% of the zonisamide circulating in the serum is bound to proteins. Zonisamide protein binding is unaffected by other common anticonvulsant drugs. The elimination half-life from plasma is 50 to 60 hours; the elimination half-life from erythrocytes is >100 hours. Since zonisamide is cleared predominantly by the kidney, the daily dosage of zonisamide given to patients with creatinine clearance <20 mL/min should be reduced.(1,2)

 

Serum level monitoring is recommended for all patients to ensure appropriate dosing because: 1) patient response correlates with serum level, 2) serum level does not correlate with dose because of concentration-dependent erythrocyte binding, 3) elimination is affected by co-administration of drugs that affect NAT1, CyP3A4, and UDPG, and 4) renal function affects elimination.

 

The most common toxicity associated with excessive serum level is drowsiness. Adverse effects not related to serum level include rash, increased serum creatinine and alkaline phosphatase, kidney stone formation, and bruising.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Forms

If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/neurology-request-form.pdf)